PhaseV
Uses advanced algorithms to optimize clinical trials, improving success rates, efficiency, and uncovering hidden signals in the data.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
* | $50.0m | Series A | |
| Total Funding | 000k | ||
| USD | 2023 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Dealroom estimates
Related Content
PhaseVTrials.com is a cutting-edge startup that specializes in developing a platform for adaptive clinical trial design and execution. The company leverages advanced technologies such as reinforcement learning and causal machine learning (ML) to optimize clinical decisions at any stage of the trial process. Their platform features an intuitive user interface and a flexible software architecture, making it accessible and adaptable for various clinical needs.
PhaseVTrials primarily serves pharmaceutical companies, biotech firms, and research institutions that are involved in drug development and clinical research. The market it operates in is the clinical trials sector, which is a critical component of the broader healthcare and pharmaceutical industries.
The business model of PhaseVTrials revolves around providing a software-as-a-service (SaaS) platform. Clients subscribe to their platform to design, manage, and execute clinical trials more efficiently. The company generates revenue through subscription fees, which can be tiered based on the level of service and features required by the client. Additionally, they may offer consulting services to help clients optimize their trial designs and execution strategies.
PhaseVTrials stands out in the market by offering a unique combination of advanced algorithms and user-friendly software. This allows clients to make data-driven decisions, potentially reducing the time and cost associated with bringing new drugs to market. The platform's ability to adapt and provide real-time insights is particularly valuable in the fast-paced and highly regulated environment of clinical trials.
In summary, PhaseVTrials.com is revolutionizing the clinical trial process with its adaptive design and execution platform, serving pharmaceutical and biotech companies with a SaaS business model that leverages advanced algorithms for optimal decision-making.
Keywords: adaptive clinical trials, reinforcement learning, causal ML, SaaS, pharmaceutical, biotech, drug development, user interface, software architecture, data-driven decisions.